Phase Ib-II Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib, w/ Lenalidomide and Rituximab in Relapsed / Refractory Mantle Cell Lymphoma
André Goy(Hackensack University Medical Center), Ernest Richards(Hackensack Meridian Health), Xiao Yan Yang(Hackensack Meridian Health), Alan P Skarbnik(Novant Health), Tatyana Feldman(Hackensack University Medical Center), Colleen M Bejot(Hackensack Meridian Health), Susan Stives(Hackensack Meridian Health), Pritish K. Bhattacharyya(Hackensack University Medical Center), Rima Panchal Panchal(Hackensack Meridian Health), Kara Yannotti(Hackensack University Medical Center), Joshua Zenreich(Hackensack University Medical Center), Themba Nyirenda(Hackensack University Medical Center), Kar Fai Chow(Hackensack Meridian Health), Lori A. Leslie(Hackensack University Medical Center)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k